市場調査レポート
商品コード
1462307
オプジーボの市場規模、予測、新薬の考察(2032年)OPDIVO Market Size, Forecast, and Emerging Insight - 2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
オプジーボの市場規模、予測、新薬の考察(2032年) |
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 30 Pages
納期: 2~10営業日
|
オプジーボ(別名ニボルマブ)は、ヒト初の免疫グロブリンG4(IgG4)PD-1免疫チェックポイント阻害抗体であり、PD-1受容体とそのリガンドであるPD-L1とPD-L2との相互作用を阻害し、細胞性免疫反応を抑制します。標的免疫療法は現在、腫瘍患者にとってもっとも有望なアプローチとなっています。活性化T細胞上に発現したPD-1は、免疫抑制を逆転させ、T細胞の活性化を解除することができます。ニボルマブはすでに確立された薬剤であり、現在、さまざまな適応症、さまざまな患者層に対して承認されています。
現在、再発上皮性卵巣がんを対象としたフェーズII臨床試験(NCT02873962)において、この薬剤の評価が進められています。
当レポートでは、主要6市場(米国・ドイツ・フランス・イタリア・スペイン・英国)における卵巣がん向けオプジーボについて調査分析し、作用機序、用法と用量、研究開発活動についての考察、収益の予測などを提供しています。
"OPDIVO Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about OPDIVO for ovarian cancer in the six major markets. A detailed picture of the OPDIVO for ovarian cancer in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom for the study period 2019 -2032 is provided in this report along with a detailed description of the OPDIVO for ovarian cancer. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the OPDIVO market forecast analysis for ovarian cancer in the 6MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ovarian cancer.
OPDIVO (also known as Nivolumab) is the first-in-human immunoglobulin G4 (IgG4) PD-1 immune checkpoint inhibitor antibody that disrupts the interaction of the PD-1 receptor with its ligands PD-L1 and PD-L2, thereby inhibiting the cellular immune response. Targeted immunotherapy has now become the most promising approach for tumor patients. PD-1 expressed on activated T-cells can reverse immune suppression and release T-cell activation. Nivolumab is an already established drug and is currently approved in different indications and for different patient segments.
Currently, the drug is being developed in a Phase II (NCT02873962) clinical study evaluating the drug in relapsed epithelial ovarian cancer.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
OPDIVO Analytical Perspective by DelveInsight
This report provides a detailed market assessment of OPDIVO for ovarian cancer in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom. This segment of the report provides forecasted sales data from 2026 to 2032.
The report provides the clinical trials information of OPDIVO for ovarian cancer covering trial interventions, trial conditions, trial status, start and completion dates.